BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 16190761)

  • 1. Alkyl-substituted polyaminohydroxamic acids: a novel class of targeted histone deacetylase inhibitors.
    Varghese S; Gupta D; Baran T; Jiemjit A; Gore SD; Casero RA; Woster PM
    J Med Chem; 2005 Oct; 48(20):6350-65. PubMed ID: 16190761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
    Suzuki T; Nagano Y; Kouketsu A; Matsuura A; Maruyama S; Kurotaki M; Nakagawa H; Miyata N
    J Med Chem; 2005 Feb; 48(4):1019-32. PubMed ID: 15715470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New aryldithiolethione derivatives as potent histone deacetylase inhibitors.
    Tazzari V; Cappelletti G; Casagrande M; Perrino E; Renzi L; Del Soldato P; Sparatore A
    Bioorg Med Chem; 2010 Jun; 18(12):4187-94. PubMed ID: 20576572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel hydroxamate and anilide derivatives as potent histone deacetylase inhibitors: synthesis and antiproliferative evaluation.
    Bouchain G; Delorme D
    Curr Med Chem; 2003 Nov; 10(22):2359-72. PubMed ID: 14529479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
    Mahboobi S; Sellmer A; Höcher H; Garhammer C; Pongratz H; Maier T; Ciossek T; Beckers T
    J Med Chem; 2007 Sep; 50(18):4405-18. PubMed ID: 17691763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alkyl piperidine and piperazine hydroxamic acids as HDAC inhibitors.
    Rossi C; Porcelloni M; D'Andrea P; Fincham CI; Ettorre A; Mauro S; Squarcia A; Bigioni M; Parlani M; Nardelli F; Binaschi M; Maggi CA; Fattori D
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2305-8. PubMed ID: 21420859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The discovery of colchicine-SAHA hybrids as a new class of antitumor agents.
    Zhang X; Zhang J; Tong L; Luo Y; Su M; Zang Y; Li J; Lu W; Chen Y
    Bioorg Med Chem; 2013 Jun; 21(11):3240-4. PubMed ID: 23602523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.
    Guan P; Sun F; Hou X; Wang F; Yi F; Xu W; Fang H
    Bioorg Med Chem; 2012 Jun; 20(12):3865-72. PubMed ID: 22579621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
    Angibaud P; Van Emelen K; Decrane L; van Brandt S; Ten Holte P; Pilatte I; Roux B; Poncelet V; Speybrouck D; Queguiner L; Gaurrand S; Mariën A; Floren W; Janssen L; Verdonck M; van Dun J; van Gompel J; Gilissen R; Mackie C; Du Jardin M; Peeters J; Noppe M; Van Hijfte L; Freyne E; Page M; Janicot M; Arts J
    Bioorg Med Chem Lett; 2010 Jan; 20(1):294-8. PubMed ID: 19906529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment.
    Chen L; Wilson D; Jayaram HN; Pankiewicz KW
    J Med Chem; 2007 Dec; 50(26):6685-91. PubMed ID: 18038969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors.
    Kim DK; Lee JY; Kim JS; Ryu JH; Choi JY; Lee JW; Im GJ; Kim TK; Seo JW; Park HJ; Yoo J; Park JH; Kim TY; Bang YJ
    J Med Chem; 2003 Dec; 46(26):5745-51. PubMed ID: 14667227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent.
    Suzuki T; Matsuura A; Kouketsu A; Hisakawa S; Nakagawa H; Miyata N
    Bioorg Med Chem; 2005 Jul; 13(13):4332-42. PubMed ID: 15927839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors.
    Liu R; Wang J; Tang W; Fang H
    Bioorg Med Chem; 2016 Apr; 24(7):1446-54. PubMed ID: 26907204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
    Bouchain G; Leit S; Frechette S; Khalil EA; Lavoie R; Moradei O; Woo SH; Fournel M; Yan PT; Kalita A; Trachy-Bourget MC; Beaulieu C; Li Z; Robert MF; MacLeod AR; Besterman JM; Delorme D
    J Med Chem; 2003 Feb; 46(5):820-30. PubMed ID: 12593661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects.
    Liao V; Liu T; Codd R
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6200-4. PubMed ID: 22932316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological characterization of amidopropenyl hydroxamates as HDAC inhibitors.
    Thaler F; Varasi M; Colombo A; Boggio R; Munari D; Regalia N; Rozio MG; Reali V; Resconi AE; Mai A; Gagliardi S; Dondio G; Minucci S; Mercurio C
    ChemMedChem; 2010 Aug; 5(8):1359-72. PubMed ID: 20572281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
    Lee S; Shinji C; Ogura K; Shimizu M; Maeda S; Sato M; Yoshida M; Hashimoto Y; Miyachi H
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4895-900. PubMed ID: 17588744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
    Oanh DT; Hai HV; Park SH; Kim HJ; Han BW; Kim HS; Hong JT; Han SB; Hue VT; Nam NH
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7509-12. PubMed ID: 22036991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.
    Salmi-Smail C; Fabre A; Dequiedt F; Restouin A; Castellano R; Garbit S; Roche P; Morelli X; Brunel JM; Collette Y
    J Med Chem; 2010 Apr; 53(8):3038-47. PubMed ID: 20218673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of the first histone deacetylase 6/8 dual inhibitors.
    Olson DE; Wagner FF; Kaya T; Gale JP; Aidoud N; Davoine EL; Lazzaro F; Weïwer M; Zhang YL; Holson EB
    J Med Chem; 2013 Jun; 56(11):4816-20. PubMed ID: 23672185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.